Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome

• Published in: Digestive diseases and sciences 2017-06, Vol.62 (6), p.1480-1485
• Main Authors: Rezaie, Ali, Park, Sung Chul, Morales, Walter, Marsh, Emily, Lembo, Anthony, Kim, Jae Hak, Weitsman, Stacy, Chua, Kathleen S., Barlow, Gillian M., Pimentel, Mark
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Analysis; Antibodies; Antibodies - blood; Bacterial Toxins - immunology; Biochemistry; Biomarkers - blood; Case-Control Studies; Constipation - blood; Constipation - diagnosis; Constipation - etiology; Diagnosis, Differential; Diarrhea; Diarrhea - blood; Diarrhea - diagnosis; Diarrhea - etiology; Enzyme-linked immunosorbent assay; Female; Gastroenterology; Hepatology; Humans; Immunoglobulins; Irritable bowel syndrome; Irritable Bowel Syndrome - blood; Irritable Bowel Syndrome - complications; Irritable Bowel Syndrome - diagnosis; Male; Medical centers; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Article; Transplant Surgery; Vinculin - immunology; Viral antibodies; Young Adult
• ISSN: 0163-2116; 1573-2568
• DOI: 10.1007/s10620-017-4585-z

Background Antibodies to cytolethal distending toxin B (CdtB) and vinculin are novel biomarkers that rule-in and differentiate irritable bowel syndrome with diarrhea (IBS-D) from other causes of diarrhea and healthy controls. Aim To determine whether these antibodies can also diagnose and differentiate other IBS subtypes. Methods Subjects with IBS-D based on Rome III criteria ( n  = 2375) were recruited from a large-scale multicenter clinical trial (TARGET 3). Healthy subjects without gastrointestinal (GI) diseases or symptoms ( n  = 43) and subjects with mixed IBS (IBS-M) ( n  = 25) or IBS with constipation (IBS-C) ( n  = 30) were recruited from two major medical centers. Plasma levels of anti-CdtB and anti-vinculin antibodies in all subjects were determined by enzyme-linked immunosorbent assay. Optical densities of ≥1.68 and ≥2.80 were considered positive for anti-vinculin and anti-CdtB, respectively. Plasma levels of anti-CdtB and anti-vinculin antibodies were highest in IBS-D and lowest in IBS-C and healthy controls ( P   0.1). Positivity for anti-CdtB or anti-vinculin resulted in a statistically significant negative gradient from IBS-D (58.1%) to IBS-M (44.0%), IBS-C (26.7%), and controls (16.3%) ( P